[HTML][HTML] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke, K Begna… - Leukemia, 2013 - nature.com
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
A Pardanani, RR Laborde, TL Lasho… - Leukemia …, 2013 - search.ebscohost.com
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho… - …, 2013 - mayoclinic.elsevierpure.com
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
[PDF][PDF] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke, K Begna… - Leukemia, 2013 - academia.edu
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm that develops de
novo (that is, primary MF, or PMF) or from antecedent polycythemia vera (PV; that is, post-PV …
novo (that is, primary MF, or PMF) or from antecedent polycythemia vera (PV; that is, post-PV …
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke… - …, 2013 - pubmed.ncbi.nlm.nih.gov
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke, K Begna… - Leukemia, 2013 - go.gale.com
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
[PDF][PDF] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke… - Leukemia, 2013 - scienceopen.com
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm that develops de
novo (that is, primary MF, or PMF) or from antecedent polycythemia vera (PV; that is, post-PV …
novo (that is, primary MF, or PMF) or from antecedent polycythemia vera (PV; that is, post-PV …
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.
A Pardanani, RR Laborde, TL Lasho, C Finke, K Begna… - Leukemia, 2013 - europepmc.org
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
[HTML][HTML] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke… - Leukemia, 2013 - ncbi.nlm.nih.gov
JAK-STAT is a rational drug target in myelofibrosis (MF) given its association with JAK2/MPL
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
mutations and aberrant inflammatory cytokine expression. We conducted a Phase 1/2 trial of …
[PDF][PDF] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani, RR Laborde, TL Lasho, C Finke… - Leukemia, 2013 - researchgate.net
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm that develops de
novo (that is, primary MF, or PMF) or from antecedent polycythemia vera (PV; that is, post-PV …
novo (that is, primary MF, or PMF) or from antecedent polycythemia vera (PV; that is, post-PV …